Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes

(MedPage Today) -- HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL inhibitor ponatinib (Iclusig), a post...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news